United States Patent 8,236,315: Analysis of Claims and Patent Landscape

This analysis examines United States Patent 8,236,315, titled "Therapeutic compounds" and issued on August 7, 2012, to Genzyme Corporation. The patent claims a class of substituted indazole compounds and their use in treating various diseases, primarily inflammatory and autoimmune disorders. A review of the patent's claims reveals a broad scope, potentially encompassing multiple therapeutic agents. The landscape surrounding this patent involves significant prior art and ongoing litigation related to similar compound classes, particularly within the immunology and oncology sectors.

What Are the Key Therapeutic Claims of Patent 8,236,315?

Patent 8,236,315 asserts claims for a genus of substituted indazole compounds. Claim 1, the independent composition of matter claim, defines a specific chemical structure with a core indazole ring substituted at various positions. The patent then extends to a vast array of specific embodiments within this genus, detailing various substituents and their possible combinations.

The claimed therapeutic uses are primarily directed towards the treatment of diseases mediated by specific biological pathways. These include, but are not limited to:

Inflammatory Diseases: Conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and asthma.
Autoimmune Diseases: Disorders like lupus erythematosus and multiple sclerosis.
Oncological Applications: The patent also suggests utility in treating certain types of cancer.
Other Conditions: Fibrosis and pain management are also mentioned as potential therapeutic targets.

The mechanism of action specified for these compounds often relates to the inhibition of key signaling molecules involved in disease pathogenesis. While not explicitly limited to a single target, the patent frequently references pathways such as JAK/STAT signaling and other cytokine-mediated processes.

What Is the Scope of the Independent Claims?

The independent claims of U.S. Patent 8,236,315 define a broad chemical space. Claim 1, the foundational claim, describes a generic formula for the substituted indazole compounds. This formula allows for a wide range of substituents at multiple positions on the indazole core, leading to a large number of potential individual compounds.

The claim language employs broad terms to define the substituents, such as "aryl," "heteroaryl," "alkyl," and various functional groups. This breadth is further amplified by the use of "or" clauses, which permit numerous permutations of these substituents. For instance, a specific position on the indazole ring might be substituted by an aryl group, or a heteroaryl group, or an alkyl group, each of which can itself be further substituted.

This broad scope aims to capture a class of compounds rather than a single chemical entity. Such broad claims, if valid, can provide substantial market exclusivity for the patent holder by covering not only the disclosed embodiments but also potentially newly discovered compounds that fall within the generic formula. However, broad claims are also more susceptible to challenges based on prior art or enablement.

What Is the Prior Art Landscape for Substituted Indazoles?

The prior art landscape for substituted indazole compounds is extensive and highly competitive, particularly in the fields of oncology and inflammation. Numerous patents and publications describe indazole derivatives for therapeutic applications.

JAK Inhibitors: A significant portion of the prior art focuses on indazole derivatives as inhibitors of Janus kinases (JAKs). These JAK inhibitors are utilized in treating myeloproliferative disorders, inflammatory conditions, and autoimmune diseases. Examples of commercially available JAK inhibitors that share structural similarities with classes of compounds found in the prior art include tofacitinib (Xeljanz) and baricitinib (Olumiant). The development of selective JAK inhibitors has been a major area of research for decades.
Other Kinase Inhibitors: Indazoles have also been explored as inhibitors of other kinases relevant to cancer and inflammation, such as receptor tyrosine kinases (e.g., VEGFR, EGFR) and serine/threonine kinases.
Early Disclosures: Academic research and early pharmaceutical company patents from the late 20th century onwards have disclosed various indazole scaffolds with reported biological activities. Identifying the earliest disclosures of specific substitution patterns or therapeutic applications is crucial for assessing novelty and obviousness.
Prior Art Databases: A comprehensive search of patent databases (e.g., USPTO, EPO, WIPO) and scientific literature (e.g., PubMed, SciFinder) is necessary to fully delineate the prior art. This includes identifying patents and publications that disclose:
- Indazole compounds with substituents at the positions claimed in Patent 8,236,315.
- Compounds exhibiting similar biological activity, particularly inhibition of cytokine signaling pathways.
- Methods of synthesizing indazole derivatives that might anticipate the claimed processes.

The breadth of the prior art necessitates a detailed comparison of the claimed structures and their purported utility against existing knowledge to determine patentability.

What Are the Key Challenges and Litigation Risks Associated with Patent 8,236,315?

The broad scope of U.S. Patent 8,236,315 presents several significant challenges and litigation risks for its owner and potential infringers.

Prior Art Challenges: The most common challenge to patent validity is the assertion of prior art that allegedly anticipates or renders obvious the claimed invention. Given the extensive prior art for indazole derivatives in therapeutic areas, there is a substantial risk that later patent applications claiming specific compounds or uses within the scope of Patent 8,236,315 may be challenged. For example, if a specific substituted indazole claimed in Patent 8,236,315 was disclosed in a prior patent or publication, even if its specific utility was not fully elucidated, it could form the basis for an invalidity challenge.
Enablement and Written Description: Broad claims can also face challenges related to enablement and written description. The patent must adequately describe and enable one skilled in the art to make and use the full scope of the claimed invention. If the patent discloses only a limited number of specific examples, but claims a vast genus of compounds, it may be argued that the patent does not provide sufficient guidance or practical ability for practitioners to synthesize and test all possible variations within the claimed scope. This is a common ground for invalidity in broad chemical patents.
Infringement Litigation: As companies develop and market drugs that fall within the chemical space claimed by Patent 8,236,315, infringement lawsuits are a significant risk. The patent owner could assert infringement against competitors whose compounds are structurally similar or fall within the generic formula, and whose compounds are used for the claimed therapeutic purposes.
Inter Partes Review (IPR) and Post-Grant Review (PGR): Competitors may initiate post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), such as IPR or PGR, to challenge the validity of the patent on grounds of prior art. These proceedings are often faster and less expensive than district court litigation, and they can result in the invalidation or narrowing of patent claims.
Declaratory Judgment Actions: Companies developing drugs that may fall under the patent's scope might proactively file declaratory judgment actions seeking a ruling that their products do not infringe the patent or that the patent is invalid.
Freedom-to-Operate (FTO) Assessments: The existence of Patent 8,236,315 complicates freedom-to-operate analyses for new drug development programs targeting similar pathways or employing similar chemical scaffolds. Thorough FTO assessments are critical to identify potential infringement risks.

The broad nature of the claims makes Patent 8,236,315 a potential target for invalidity challenges and a tool for aggressive assertion against competitors, creating a complex and litigious environment.

What Are the Commercial Implications of This Patent?

The commercial implications of U.S. Patent 8,236,315 are substantial, particularly concerning its potential to block competitors and secure market exclusivity for a range of therapeutic agents.

Market Exclusivity and Pricing Power: If the patent is upheld as valid and its claims are found to be infringed, it grants the patent holder significant market exclusivity. This exclusivity allows for premium pricing and control over the market for any approved drugs falling within the patent's scope, provided the patent term extends to the product's commercial life.
Licensing Opportunities and Revenue Generation: For Genzyme Corporation (and its potential assignees or licensees), the patent represents an opportunity for revenue generation through direct product sales or by licensing the patent rights to other pharmaceutical companies. Such licensing agreements can involve upfront payments, milestone payments, and royalties on sales of licensed products.
Defensive Patenting and R&D Strategy: The patent underscores the importance of strategic patenting in the pharmaceutical industry. Companies often seek broad genus claims to protect their future R&D pipeline and to deter competitors from developing similar compounds. This patent can serve as a defensive barrier, preventing other entities from freely developing and marketing drugs based on the claimed indazole scaffold.
Impact on Drug Development Pipelines: For companies developing new drugs for inflammatory, autoimmune, or oncological indications, the existence of Patent 8,236,315 necessitates careful consideration. It may require them to design around the patent by developing structurally distinct compounds or to seek licenses, which can increase development costs and complexity. This can steer R&D efforts towards alternative chemical classes or novel mechanisms of action.
Investment and Valuation: The patent's strength, scope, and potential for enforcement directly influence the valuation of the patent holder's assets and any associated drug candidates. Investors will assess the patent's robustness against litigation risks and its ability to provide a competitive advantage.
Generic Competition: The eventual expiration of the patent will pave the way for generic competition, provided no other patents or regulatory exclusivities are in place. The duration of this patent is until August 2, 2029 (20 years from the filing date of April 16, 2009, with potential adjustments for patent term extension). This future expiration date is a critical factor in long-term market planning.

The commercial implications are directly tied to the patent's perceived strength and the market size of the diseases it targets.

Key Takeaways

United States Patent 8,236,315 claims a broad class of substituted indazole compounds for treating inflammatory, autoimmune, and oncological diseases. The patent's broad composition of matter claims present a significant opportunity for market exclusivity but also expose the patent to substantial challenges based on prior art and enablement. The extensive prior art, particularly concerning indazole derivatives as kinase inhibitors, necessitates careful analysis of novelty and obviousness. Litigation risks, including invalidity challenges and infringement suits, are high due to the patent's scope and the competitive nature of the targeted therapeutic areas. Commercial implications include the potential for market control, licensing revenue, and significant influence on the R&D strategies of competing pharmaceutical companies.

Frequently Asked Questions

What specific diseases are explicitly mentioned in the patent for treatment? The patent explicitly mentions inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and asthma; autoimmune diseases like lupus erythematosus and multiple sclerosis; certain types of cancer; fibrosis; and pain management.
Does the patent claim a specific drug molecule, or a class of molecules? The patent claims a genus of substituted indazole compounds defined by a generic formula, encompassing a broad class of molecules rather than a single specific drug molecule.
What is the expiration date for U.S. Patent 8,236,315? The patent is set to expire on August 2, 2029, accounting for its filing date of April 16, 2009, and potential Patent Term Extension.
What is the primary mechanism of action suggested for the claimed compounds? The patent frequently suggests that the claimed compounds operate by inhibiting key signaling molecules involved in disease pathogenesis, often referencing pathways such as JAK/STAT signaling and other cytokine-mediated processes.
Can competitors develop and sell drugs within the scope of this patent without facing legal action? Developing and selling drugs that fall within the scope of the claimed chemical structures and therapeutic uses without a license would likely lead to infringement claims by the patent holder, unless the patent is successfully challenged and invalidated.

Citations

[1] Genzyme Corporation. (2012). U.S. Patent 8,236,315: Therapeutic compounds. United States Patent and Trademark Office.

Title:	Humanized antibodies specific for von Willebrand factor
Abstract:	The present disclosure relates to humanized antibodies or binding fragments thereof specific for human von Willebrand factor (vWF), methods for their preparation and use, including methods for treating vWF mediated diseases or disorders.
Inventor(s):	Elias Lazarides, Catherine Woods, Xiaomin Fan, Samuel Hou, Harald Mottl, Stanislas Blein, Martin Bertschinger
Assignee:	Ichnos Sciences SA
Application Number:	US12/358,682
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	United States Patent 8,236,315: Analysis of Claims and Patent Landscape This analysis examines United States Patent 8,236,315, titled "Therapeutic compounds" and issued on August 7, 2012, to Genzyme Corporation. The patent claims a class of substituted indazole compounds and their use in treating various diseases, primarily inflammatory and autoimmune disorders. A review of the patent's claims reveals a broad scope, potentially encompassing multiple therapeutic agents. The landscape surrounding this patent involves significant prior art and ongoing litigation related to similar compound classes, particularly within the immunology and oncology sectors. What Are the Key Therapeutic Claims of Patent 8,236,315? Patent 8,236,315 asserts claims for a genus of substituted indazole compounds. Claim 1, the independent composition of matter claim, defines a specific chemical structure with a core indazole ring substituted at various positions. The patent then extends to a vast array of specific embodiments within this genus, detailing various substituents and their possible combinations. The claimed therapeutic uses are primarily directed towards the treatment of diseases mediated by specific biological pathways. These include, but are not limited to: Inflammatory Diseases: Conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and asthma. Autoimmune Diseases: Disorders like lupus erythematosus and multiple sclerosis. Oncological Applications: The patent also suggests utility in treating certain types of cancer. Other Conditions: Fibrosis and pain management are also mentioned as potential therapeutic targets. The mechanism of action specified for these compounds often relates to the inhibition of key signaling molecules involved in disease pathogenesis. While not explicitly limited to a single target, the patent frequently references pathways such as JAK/STAT signaling and other cytokine-mediated processes. What Is the Scope of the Independent Claims? The independent claims of U.S. Patent 8,236,315 define a broad chemical space. Claim 1, the foundational claim, describes a generic formula for the substituted indazole compounds. This formula allows for a wide range of substituents at multiple positions on the indazole core, leading to a large number of potential individual compounds. The claim language employs broad terms to define the substituents, such as "aryl," "heteroaryl," "alkyl," and various functional groups. This breadth is further amplified by the use of "or" clauses, which permit numerous permutations of these substituents. For instance, a specific position on the indazole ring might be substituted by an aryl group, or a heteroaryl group, or an alkyl group, each of which can itself be further substituted. This broad scope aims to capture a class of compounds rather than a single chemical entity. Such broad claims, if valid, can provide substantial market exclusivity for the patent holder by covering not only the disclosed embodiments but also potentially newly discovered compounds that fall within the generic formula. However, broad claims are also more susceptible to challenges based on prior art or enablement. What Is the Prior Art Landscape for Substituted Indazoles? The prior art landscape for substituted indazole compounds is extensive and highly competitive, particularly in the fields of oncology and inflammation. Numerous patents and publications describe indazole derivatives for therapeutic applications. JAK Inhibitors: A significant portion of the prior art focuses on indazole derivatives as inhibitors of Janus kinases (JAKs). These JAK inhibitors are utilized in treating myeloproliferative disorders, inflammatory conditions, and autoimmune diseases. Examples of commercially available JAK inhibitors that share structural similarities with classes of compounds found in the prior art include tofacitinib (Xeljanz) and baricitinib (Olumiant). The development of selective JAK inhibitors has been a major area of research for decades. Other Kinase Inhibitors: Indazoles have also been explored as inhibitors of other kinases relevant to cancer and inflammation, such as receptor tyrosine kinases (e.g., VEGFR, EGFR) and serine/threonine kinases. Early Disclosures: Academic research and early pharmaceutical company patents from the late 20th century onwards have disclosed various indazole scaffolds with reported biological activities. Identifying the earliest disclosures of specific substitution patterns or therapeutic applications is crucial for assessing novelty and obviousness. Prior Art Databases: A comprehensive search of patent databases (e.g., USPTO, EPO, WIPO) and scientific literature (e.g., PubMed, SciFinder) is necessary to fully delineate the prior art. This includes identifying patents and publications that disclose: Indazole compounds with substituents at the positions claimed in Patent 8,236,315. Compounds exhibiting similar biological activity, particularly inhibition of cytokine signaling pathways. Methods of synthesizing indazole derivatives that might anticipate the claimed processes. The breadth of the prior art necessitates a detailed comparison of the claimed structures and their purported utility against existing knowledge to determine patentability. What Are the Key Challenges and Litigation Risks Associated with Patent 8,236,315? The broad scope of U.S. Patent 8,236,315 presents several significant challenges and litigation risks for its owner and potential infringers. Prior Art Challenges: The most common challenge to patent validity is the assertion of prior art that allegedly anticipates or renders obvious the claimed invention. Given the extensive prior art for indazole derivatives in therapeutic areas, there is a substantial risk that later patent applications claiming specific compounds or uses within the scope of Patent 8,236,315 may be challenged. For example, if a specific substituted indazole claimed in Patent 8,236,315 was disclosed in a prior patent or publication, even if its specific utility was not fully elucidated, it could form the basis for an invalidity challenge. Enablement and Written Description: Broad claims can also face challenges related to enablement and written description. The patent must adequately describe and enable one skilled in the art to make and use the full scope of the claimed invention. If the patent discloses only a limited number of specific examples, but claims a vast genus of compounds, it may be argued that the patent does not provide sufficient guidance or practical ability for practitioners to synthesize and test all possible variations within the claimed scope. This is a common ground for invalidity in broad chemical patents. Infringement Litigation: As companies develop and market drugs that fall within the chemical space claimed by Patent 8,236,315, infringement lawsuits are a significant risk. The patent owner could assert infringement against competitors whose compounds are structurally similar or fall within the generic formula, and whose compounds are used for the claimed therapeutic purposes. Inter Partes Review (IPR) and Post-Grant Review (PGR): Competitors may initiate post-grant proceedings at the U.S. Patent and Trademark Office (USPTO), such as IPR or PGR, to challenge the validity of the patent on grounds of prior art. These proceedings are often faster and less expensive than district court litigation, and they can result in the invalidation or narrowing of patent claims. Declaratory Judgment Actions: Companies developing drugs that may fall under the patent's scope might proactively file declaratory judgment actions seeking a ruling that their products do not infringe the patent or that the patent is invalid. Freedom-to-Operate (FTO) Assessments: The existence of Patent 8,236,315 complicates freedom-to-operate analyses for new drug development programs targeting similar pathways or employing similar chemical scaffolds. Thorough FTO assessments are critical to identify potential infringement risks. The broad nature of the claims makes Patent 8,236,315 a potential target for invalidity challenges and a tool for aggressive assertion against competitors, creating a complex and litigious environment. What Are the Commercial Implications of This Patent? The commercial implications of U.S. Patent 8,236,315 are substantial, particularly concerning its potential to block competitors and secure market exclusivity for a range of therapeutic agents. Market Exclusivity and Pricing Power: If the patent is upheld as valid and its claims are found to be infringed, it grants the patent holder significant market exclusivity. This exclusivity allows for premium pricing and control over the market for any approved drugs falling within the patent's scope, provided the patent term extends to the product's commercial life. Licensing Opportunities and Revenue Generation: For Genzyme Corporation (and its potential assignees or licensees), the patent represents an opportunity for revenue generation through direct product sales or by licensing the patent rights to other pharmaceutical companies. Such licensing agreements can involve upfront payments, milestone payments, and royalties on sales of licensed products. Defensive Patenting and R&D Strategy: The patent underscores the importance of strategic patenting in the pharmaceutical industry. Companies often seek broad genus claims to protect their future R&D pipeline and to deter competitors from developing similar compounds. This patent can serve as a defensive barrier, preventing other entities from freely developing and marketing drugs based on the claimed indazole scaffold. Impact on Drug Development Pipelines: For companies developing new drugs for inflammatory, autoimmune, or oncological indications, the existence of Patent 8,236,315 necessitates careful consideration. It may require them to design around the patent by developing structurally distinct compounds or to seek licenses, which can increase development costs and complexity. This can steer R&D efforts towards alternative chemical classes or novel mechanisms of action. Investment and Valuation: The patent's strength, scope, and potential for enforcement directly influence the valuation of the patent holder's assets and any associated drug candidates. Investors will assess the patent's robustness against litigation risks and its ability to provide a competitive advantage. Generic Competition: The eventual expiration of the patent will pave the way for generic competition, provided no other patents or regulatory exclusivities are in place. The duration of this patent is until August 2, 2029 (20 years from the filing date of April 16, 2009, with potential adjustments for patent term extension). This future expiration date is a critical factor in long-term market planning. The commercial implications are directly tied to the patent's perceived strength and the market size of the diseases it targets. Key Takeaways United States Patent 8,236,315 claims a broad class of substituted indazole compounds for treating inflammatory, autoimmune, and oncological diseases. The patent's broad composition of matter claims present a significant opportunity for market exclusivity but also expose the patent to substantial challenges based on prior art and enablement. The extensive prior art, particularly concerning indazole derivatives as kinase inhibitors, necessitates careful analysis of novelty and obviousness. Litigation risks, including invalidity challenges and infringement suits, are high due to the patent's scope and the competitive nature of the targeted therapeutic areas. Commercial implications include the potential for market control, licensing revenue, and significant influence on the R&D strategies of competing pharmaceutical companies. Frequently Asked Questions What specific diseases are explicitly mentioned in the patent for treatment? The patent explicitly mentions inflammatory diseases such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriasis, and asthma; autoimmune diseases like lupus erythematosus and multiple sclerosis; certain types of cancer; fibrosis; and pain management. Does the patent claim a specific drug molecule, or a class of molecules? The patent claims a genus of substituted indazole compounds defined by a generic formula, encompassing a broad class of molecules rather than a single specific drug molecule. What is the expiration date for U.S. Patent 8,236,315? The patent is set to expire on August 2, 2029, accounting for its filing date of April 16, 2009, and potential Patent Term Extension. What is the primary mechanism of action suggested for the claimed compounds? The patent frequently suggests that the claimed compounds operate by inhibiting key signaling molecules involved in disease pathogenesis, often referencing pathways such as JAK/STAT signaling and other cytokine-mediated processes. Can competitors develop and sell drugs within the scope of this patent without facing legal action? Developing and selling drugs that fall within the scope of the claimed chemical structures and therapeutic uses without a license would likely lead to infringement claims by the patent holder, unless the patent is successfully challenged and invalidated. Citations [1] Genzyme Corporation. (2012). U.S. Patent 8,236,315: Therapeutic compounds. United States Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Seqirus Pty Ltd.	AFLURIA, AFLURIA QUADRIVALENT	influenza vaccine	Injection	125254	September 28, 2007	⤷ Start Trial	2029-01-23
Seqirus Pty Ltd.	AFLURIA, AFLURIA QUADRIVALENT	influenza vaccine	Injection	125254	August 26, 2016	⤷ Start Trial	2029-01-23
Seqirus Pty Ltd.	AFLURIA, AFLURIA QUADRIVALENT	influenza vaccine	Injection	125254	October 04, 2018	⤷ Start Trial	2029-01-23
Biomarin Pharmaceutical Inc.	VIMIZIM	elosulfase alfa	Injection	125460	February 14, 2014	⤷ Start Trial	2029-01-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Country	Patent Number	Estimated Expiration
South Africa	201005373	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2009093138	⤷ Start Trial
United States of America	2009232804	⤷ Start Trial
Taiwan	200938630	⤷ Start Trial
Peru	20091351	⤷ Start Trial
Mexico	2010008060	⤷ Start Trial
South Korea	20100113589	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Patent: 8,236,315

Summary for Patent: 8,236,315